Ceftaroline Fosamil in Subjects With Staphylococcus aureus Bacteremia or With Persistent Methicillin-Resistant Staphylococcus aureus Bacteremia

-
Investigator: Henry Chambers, MD
Sponsor: Cerexa, Inc

Location(s): United States

Description

This is a study of safety and efficacy of ceftaroline fosamil in Subjects with Staphylococcus aureus Bacteremia or with Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia persisting after at least 72 hours of vancomycin and/or daptomycin treatment.